The Law Office of Robbins Umeda LLP Announces an Investigation of the Acquisition of Martek Biosciences Corp. by Royal DSM N.V.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors ("Board") of Martek Biosciences Corporation ("Martek" or the "Company") (NASDAQ: MATK) in connection with their efforts to sell Martek to Royal DSM N.V. ("DSM") (Euronext: DSM KON). The transaction will be accomplished through an all-cash tender offer. If the transaction is completed, Martek shareholders will receive $31.50 in cash for each share of Martek common stock they hold. The tender offer is expected to commence in January 2011 and is expected to close in February 2011.

Robbins Umeda LLP's investigation concerns whether Martek's Board undertook a fair process to obtain fair consideration for all shareholders of Martek. Specifically, our investigation concerns whether members of the Company's Board breached their fiduciary duties to Martek shareholders by failing to adequately shop the Company before entering into the transaction with DSM.

If you are a shareholder of Martek, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at [e-mail].

Robbins Umeda LLP represents individual and institutional shareholders in derivative, direct, and class action lawsuits. The law firm's skilled litigation teams include former federal prosecutors, former defense counsel from top multinational corporate law firms, and career shareholder rights lawyers. Robbins Umeda LLP has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. For more information, please go to http://www.robbinsumeda.com.

Attorney Advertising. Past results do not guarantee a similar outcome. We invite you to contact us today to discuss your case.